{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:22Z","timestamp":1790996182893,"version":"4.1.0"},"reference-count":160,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"National Recovery and Resilience Plan","award":["PE0000006\/DN.1553"],"award-info":[{"award-number":["PE0000006\/DN.1553"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/17425255.2025.2510302","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T01:28:18Z","timestamp":1748568498000},"page":"847-864","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Drug-drug interaction between anti-seizure medications in Dravet syndrome and Lennox-Gastaut syndrome"],"prefix":"10.1080","volume":"21","author":[{"given":"Roberta","family":"Roberti","sequence":"first","affiliation":[{"name":"Magna Gr\u00e6cia University","place":["Catanzaro, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-5571","authenticated-orcid":false,"given":"Antonella","family":"Riva","sequence":"additional","affiliation":[{"name":"University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[{"name":"University of Genoa","place":["Genoa, Italy"]},{"name":"IRCCS Istituto Giannina Gaslini, full member of ERN-EPICARE","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-8123","authenticated-orcid":false,"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[{"name":"Magna Gr\u00e6cia University","place":["Catanzaro, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17866"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12832"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17932"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17239"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003716"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.07.004"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17241"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2017.01.025"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.06.021"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17274"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00505"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00898-1"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2014.0714"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.20069"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-82790-8"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2223960"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1652"},{"key":"e_1_3_5_20_1","unstructured":"FDA. EPIDIOLEX\u00ae (cannabidiol) prescribing information Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/210365s021lbl.pdf"},{"key":"e_1_3_5_21_1","unstructured":"EMA. Epidyolex: EPAR - Product information [Internet]. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/epidyolex-epar-product-information_en.pdf"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13634"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14555"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0578-5"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-25.1.75"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2019.1123"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1262"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16674"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16542"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16546"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00726-4"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.665"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1834383"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00819-8"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00784-8"},{"key":"e_1_3_5_36_1","unstructured":"EMA. Clobazam. Summary of product characteristics [Internet]. 2021. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/15103\/smpc#about-medicine"},{"key":"e_1_3_5_37_1","unstructured":"FDA. ONFI\u00ae (clobazam). Prescribing information [Internet]. 2011. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/202067s008 203993s010lbl.pdf"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12717"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17515"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31825dc4a6"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.007237"},{"key":"e_1_3_5_42_1","unstructured":"EMA. Diacomit: EPAR-Product information. 2024."},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199912000-00004"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199208000-00002"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12951"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.8.1540"},{"key":"e_1_3_5_47_1","unstructured":"FDA. Felbatol\u00ae (felbamate). Prescribing information [internet]. 2012 [cited 2025 Mar 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020189s022lbl.pdf"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.06.020"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921030-00006"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01041.x"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02529.x"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1991.tb04669.x"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.4.1106"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.170"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12815"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198511283132219"},{"key":"e_1_3_5_57_1","unstructured":"EMA. Summary of product characteristics [Internet]. Fenfluramine. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fintepla-epar-product-information_en.pdf"},{"key":"e_1_3_5_58_1","unstructured":"FDA. FINTEPLA\u00ae (fenfluramine): prescribing information [Internet]. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212102s013lbl.pdf"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.05.013"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP203276"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90044-8"},{"key":"e_1_3_5_62_1","unstructured":"EMA. Summary of product characteristics [Internet]. Lamotrigine. 2008 [cited 2024 Dec 4]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lamictal-article-30-referral-annex-i-ii-iii_en.pdf"},{"key":"e_1_3_5_63_1","unstructured":"FDA. LAMICTAL (lamotrigine). Prescribing information [internet]. 2021 [cited 2024 Dec 4]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020241s064 020764s057 022251s028lbl.pdf"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12593"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.9.1432"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31817fd4d4"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01233.x"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199610000-00001"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01665.x"},{"key":"e_1_3_5_70_1","unstructured":"FDA. XCOPRI. Prescribing information [Internet]. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212839s009s010lbl.pdf"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13852"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04228.x"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04079.x"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7597.2004.04515.x"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18101"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1980.tb04073.x"},{"key":"e_1_3_5_77_1","unstructured":"FDA. Valproic acid. Prescribing information [Internet]. 2020 [cited 2024 Nov 30]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018081s065_018082s048lbl.pdf"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01356.x"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.10.002"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2001.0555"},{"key":"e_1_3_5_81_1","unstructured":"EMA. Rufinamide: EPAR-Product characteristics [internet]. 2023 [cited 2025 Jan 19]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inovelon-epar-product-information_en.pdf"},{"key":"e_1_3_5_82_1","unstructured":"FDA. Prescribing information [internet]. Rufinamide. 2019 [cited 2025 Jan 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021911s017 201367s008lbl.pdf"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.04.057"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31820fa9ad"},{"key":"e_1_3_5_85_1","unstructured":"FDA. DIACOMIT (stiripentol). Prescribing information [Internet]. 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206709s000 207223s000lbl.pdf"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02813-0"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.237"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12918"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200217666160322143504"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05372.x"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00110-7"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06154.x"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03532.x"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01124.x"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199803000-00004"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)01001-7"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1983.04050120047006"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1177\/088307389701200311"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011426875"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1600112"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2012.12.039"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)01007-8"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91398-6"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90130-7"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18075"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231191000"},{"key":"e_1_3_5_107_1","unstructured":"ClinicalTrials.gov. A study of Soticlestat as an add-on therapy in children and young adults with Dravet syndrome [Internet]. 2025 [cited 2025 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04940624?tab=results"},{"key":"e_1_3_5_108_1","unstructured":"ClinicalTrials.gov. A study of Soticlestat as an add-on therapy in children teenagers and adults with Lennox-Gastaut syndrome. [Internet]. 2024 [cited 2025 Mar 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04938427?tab=results"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2373350"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01027-2"},{"key":"e_1_3_5_111_1","unstructured":"EMA. Ganaxolone: EPAR - Product information [Internet]. 2024 [cited 2025 Mar 9]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ztalmy-epar-product-information_en.pdf"},{"key":"e_1_3_5_112_1","unstructured":"FDA. ZTALMY\u00ae (ganaxolone). Prescribing information [internet]. 2023 [cited 2025 Mar 9]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215904s003s004lbl.pdf"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00077-1"},{"key":"e_1_3_5_114_1","unstructured":"Marsh E Flatt J Aimetti A et al. Effect of ganaxolone in patients with features of Lennox-gastaut syndrome: post-hoc analysis from a clinical trial in CDKL5 deficiency disorder [internet]. Abstract. 2024 [cited 2025 Mar 9]. Available from: https:\/\/aesnet.org\/abstractslisting\/effect-of-ganaxolone-in-patients-with-features-of-lennox-gastaut-syndrome-post-hoc-analysis-from-a-clinical-trial-in-cdkl5-deficiency-disorder"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2024.08.022"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.22037\/ijcn.v15i4.29819"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106541"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109561"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00569"},{"key":"e_1_3_5_120_1","unstructured":"FDA. BRIVIACT\u00ae (brivaracetam). Prescribing information [internet]. 2023 [cited 2024 Dec 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/205836s014 205837s011 205838s011lbl.pdf"},{"key":"e_1_3_5_121_1","unstructured":"EMA. Summary of product characteristics [Internet]. Brivaracetam. 2024 [cited 2024 Dec 6]. Available from: http:\/\/www.ema.europa.eu\/en\/documents\/product-information\/briviact-epar-product-information_en.pdf"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107146"},{"key":"e_1_3_5_123_1","unstructured":"EMA. Briviact: EPAR - Product information [Internet]. 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/briviact-epar-product-information_en.pdf"},{"key":"e_1_3_5_124_1","unstructured":"FDA. Briviact. Prescribing information [internet]. 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/205836Orig1s000 205837Orig1s000 205838Orig1s000lbl.pdf"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16071"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2230-6"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.761"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16500"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106327"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12433"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010129"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205211"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17427"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13204"},{"key":"e_1_3_5_135_1","unstructured":"EMA. Summary of product characteristics. [Internet]. ONTOZRY. 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ontozry-epar-product-information_en.pdf"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16726"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109156"},{"key":"e_1_3_5_138_1","unstructured":"FDA. FYCOMPA\u00ae (perampanel). Prescribing information [internet]. 2023 [cited 2025 Mar 6]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/202834Orig1s019lbl.pdf"},{"key":"e_1_3_5_139_1","unstructured":"EMA. Summary of product characteristics [Internet]. Perampanel. 2023 [cited 2025 Mar 6]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fycompa-epar-product-information_en.pdf"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1182304"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.05.036"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2019.12.012"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17601"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108836"},{"key":"e_1_3_5_145_1","unstructured":"ClinicalTrials.gov. Study of perampanel as adjunctive treatment for inadequately controlled seizures associated with Lennox-Gastaut syndrome [Internet]. 2022 [cited 2025 Mar 7]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT02834793"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2019.02.014"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2019.12.024"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17530"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2024.107339"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12865"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2020.1182"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14446"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106367"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000274"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12240"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00955-9"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1903429"},{"key":"e_1_3_5_158_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2278676"},{"key":"e_1_3_5_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.02.014"},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00835-4"},{"key":"e_1_3_5_161_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16539"},{"key":"e_1_3_5_162_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-023-00676-9"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2025.2510302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:52:22Z","timestamp":1751352742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2025.2510302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":160,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/17425255.2025.2510302"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2025.2510302","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}